The Column Group — Full Portfolio
71 tracked investments · listed companies and verified rows first
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Edward Mead JohnsonJames Wood JohnsonRobert Wood Johnson IJoaquin DuatoinJ. Duato(Chief Executive Officer)
Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESvenBio Partners
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestTaiho Ventures, LLCOrbiMed
Revolution Medicines develops drug candidates targeting specific genetic mutations in cancer and other serious diseases, advancing them through clinical trials toward regulatory approval and commercialization.
BiotechRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Co-investorsBain Capital Life SciencesForesite CapitalNextech InvestThird Rock Ventures
Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)inEric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)inSheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in
Co-investorsGV (Google Ventures)venBio Partners
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Board seatJeff Goater· per SEC Form D
Co-investorsAtlas VentureForesite CapitalARCH Venture PartnersDecheng Capital
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)in
Co-investorsLux CapitalRA CapitalNextech Invest
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)inAmanda J. Redig(Chief Medical Officer)inScott Lesley(President & CSO)inPamela Holland(SVP of Biology)inSally Johnson(Chief People Officer)in
Co-investorsMRL Ventures FundVida Ventures
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesDroia VenturesYK Bioventures
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsSamsara BioCapitalSanofi Ventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatDavid Goeddel· per SEC Form D
Co-investorsNextech InvestVida VenturesSamsara BioCapital
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Board seatJohn JoseyJames EvangelistaPeter Svennilson· per SEC Form D
Co-investorsBerkeley CatalystHemisphere Ventures LLCLifeforce CapitalMission Bay CapitalMission BiocapitalNextech Invest+2 more
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Board seatPeter SvennilsonDavid Goeddel· per SEC Form D · $100M raise · filed Apr 2018
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThird Rock Ventures
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inDaniel Becker(Director)
Board seatJohn Josey· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersRA Capital
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)inMaureen E. Hillenmeyer(Executive Officer, Director)inMaureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Board seatDavid Goeddel· per SEC Form D
Co-investorsB3 HoldingNextech InvestSoftBank Vision Fund8VCCasdin CapitalTwo Sigma Ventures
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)
BoardTerry McGuire(Director)inJoshua Wolfe(Director)in
Board seatTim Kutzkey· per SEC Form D
Co-investorsDns CapitalIllumina VenturesLux CapitalPolaris PartnersTwo Sigma Ventures
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Board seatPeter SvennilsonTim KutzkeyDavid Goeddel· per SEC Form D
Co-investorsBerkeley FrontierIaso VenturesYsios CapitalAlexandriaFidelity InvestmentsLYFE Capital+7 more
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway.
BiotechHealthtechSouth San Francisco, US
Diana Peng Bockus(Executive Officer, Director)
BoardRoger M. Perlmutter(Director)
Board seatPeter SvennilsonTim Kutzkey· per SEC Form D
Co-investorsRho Ventures
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardMark Goldsmith(Director)
Board seatDavid Goeddel· per SEC Form D
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalSofinnova Ventures
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Board seatJeff Goater· per SEC Form D · $25M raise · filed Dec 2022
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieNovartis Venture Fund
A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Jim Robinson(CEO)in
Co-investorsSamsara BioCapital
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)JJDCJohnson & Johnson Innovation – JJDC+1 more
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVC+2 more
Tau provides formal verification of compiled binaries by generating mathematical proofs of correctness or identifying bugs, addressing risks from AI-assisted code generation and complex software systems.
AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US
Pedro Nobre(Founder)inLuke Johnston(Founder)in
Co-investorsY CombinatorLux Capital
Cajal Therapeutics develops novel therapies through translating scientific advances into treatments for patients.
AI & Machine LearningBiotechMedical DevicesSeattle, US
Andrew Dervan(Co-Founder and Co-Chief Executive Officer)inIan Peikon(Co-Founder and Co-Chief Executive Officer)inRob Hershberg(Co-Founder and Executive Chairman)in
Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.
BiotechSouth San Francisco, US
Susan M. Molineaux(Executive Officer, Director)inWilliam Waddill(Executive Officer)in
BoardJean M. George(Director)Deepa Pakianathan(Director)inRalph E. Christoffersen(Director)Jonathan Drachman(Director)
Co-investorsLongwood FundVenture Capital Investment Management
Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.
BiotechDeep TechHealthtechBoston, US
Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in
Co-investorsAstellas Venture Management LLCThird Rock VenturesEisai Innovation, Inc.Ono Venture Investment, Inc.
BiotechSan Carlos, US
Juan Carlos Jaen(Executive Officer, Director)inTerry Rosen(Executive Officer, Director)inLuis Bayol(Executive Officer)in
BoardBeth Seidenberg(Director)inDave Goeddel(Director)William Rieflin(Director)
Co-investorsKleiner Perkins
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
BiotechDeep TechHealthtechMedical Devices
Howard Federoff(Scientific Co-Founder, Chief Medical Officer and Executive Vice President of Corporate Medicine and Science)in
Co-investorsCure Ventures
Kimia is a therapeutics company developing new drugs through its ATLAS platform, working with partners in the pharmaceutical and biotechnology industries.
AI & Machine LearningBiotechDeep Tech
Stig Hansen(Founder)in
Co-investorsHorizons VenturesAirTree VenturesBlackbird VenturesDIMENSIONDimension CapitalSkip Capital
Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers.
BiotechDeep TechHealthtechSouth San Francisco, US
NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.
Circular EconomyCleantechNew Materials
Co-investorsArc AngelsIcehouse Ventures
Nilo Saúde provides AI agents and automation solutions designed for healthcare institutions to improve operational efficiency and financial outcomes.
AI & Machine LearningDigital HealthHealthtech
Co-investorsTau VenturesMAYA Capital VenturesThe Fund
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)DCVC BioLux Capital
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsNextech InvestVida Ventures
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)in
BoardSerge Messerlian(Director)inCariad Chester(Director)in
Co-investorsCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesSoftBank Vision FundTCG Crossover+2 more
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.
BiotechHealthtech
Co-investorsForesite CapitalFrazier Life SciencesKleiner PerkinsMedicxiSolasta VenturesOrbiMed
Carmot is a clinical-stage biotechnology company developing novel treatments for obesity and type 2 diabetes through biased receptor agonist compounds.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsHorizons VenturesTCG Crossover
Constellation Pharmaceuticals was a Cambridge, MA clinical-stage biopharmaceutical company developing epigenetics-based cancer therapies, including BET and EZH2 inhibitors.
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesExSight VenturesLongitude CapitalTachyon Ventures
Co-investorsEcoR1 CapitalHorizons VenturesLux CapitalTCG CrossoverInnovation Endeavors
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesAbingworth+3 more
Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.
BiotechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsFrazier Life SciencesGV (Google Ventures)
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
Co-investorsAisling CapitalAtlas VentureHM Venture PartnersSanderling VenturesSPRINGROCK VENTURES
Monimoit develops cancer therapeutics by combining chemical proteomics, covalent-based molecular technologies, and patient-derived translational insights to target difficult-to-drug cancer-promoting proteins and overcome resistance to existing treatments.
BiotechDeep Tech
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical Devices
Co-investorsGen CapitalIllinois VenturesNextech Invest
Genentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
AI & Machine LearningBiotechDigital HealthSouth San Francisco, US
Co-investorsAisling CapitalKleiner PerkinsNew Enterprise Associates (NEA)
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical Devices
Co-investorsAccess Biotechnology
SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists.
AI & Machine LearningBiotechDeep Tech
Maria Soloveychik(PhD)in
Co-investorsNorth South VenturesOMX Ventures8VC
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsAN Venture PartnersCure Ventures
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.
BiotechHealthtechCambridge, US
Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)
BoardKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Co-investorsSR One Capital ManagementMRL Ventures Fund
Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need.
BiotechDeep TechHealthtechMedical Devices
David(Co-Founder)Maria Grazia Roncarolo(Co-Founder, President and Head of R&D)
Co-investorsNeva Sgr.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Carmot Therapeutics Inc.Exonics TherapeuticsFLX BioIgenica BiotherapeuticsNgm BiopharmaceuticalsRYNE Biotechnology Inc.Site Tx, Inc.SurrozenAragon PharmaceuticalsBE BiopharmaCajal NeuroscienceCarmot TherapeuticsCleave TherapeuticsEikon TherapeuticsGritstone BioKenai TherapeuticsSmall MoleculesThumbnail for Exonics TherapeuticsTr1x
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.